Mylan and Mapi Pharma Partner on Once Monthly Glatiramer Acetate Drug for Relapsing-Remitting MS

Mylan and Mapi Pharma announced today that the two companies will partner on the development and commercialization of GA Depot, a long-acting Glatiramer Acetate product. Mylan is acquiring global marketing rights to the product. GA Depot is a proposed once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis.